Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319103 | 0.84 | ALOX5 (0.41) | ALDH1A1ALOX5MEN1KMT2A | |
| SCHEMBL1913578 | 0.83 | L3MBTL1 (0.49) | CTSB | |
| SCHEMBL1913579 | 0.83 | L3MBTL1 (0.49) | CTSB | |
| SCHEMBL5270550 | 0.81 | MEN1 (0.38) | ALDH1A1CTSBALOX5MEN1KMT2A | |
| SCHEMBL9563422 | 0.81 | MEN1 (0.38) | ALDH1A1CTSBALOX5MEN1KMT2A | |
| SCHEMBL3209123 | 0.79 | ALDH1A1 (0.43) | ALDH1A1ALOX5MEN1KMT2A | |
| SCHEMBL4973395 | 0.78 | ALDH1A1 (0.42) | ALDH1A1ALOX5MEN1KMT2A | |
| SCHEMBL28343493 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALOX5MEN1KMT2ASLC1A3 | |
| SCHEMBL8900203 | 0.78 | ALOX5 (0.45) | ALDH1A1ALOX5MEN1KMT2A | |
| SCHEMBL10558457 | 0.76 | ALDH1A1 (0.47) | ALDH1A1CTSBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011069149-A2 | CATHEPSIN S INHIBITORS | DCB-USA LLC (US) | 2011-06-09 | — | — | WO | disclosed |
| US-7820680-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080009490-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009490-A1 | Hiv Integrase Inhibitors | TYMS, UNG, TYMP | ALDH1A1 1556/4885CTSB 2527/4885ALOX5 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.